Science Explorer Interactive view Map
Company · Newark · United States

Protagonist Therapeutics (United States)

protagonist-inc.comROR OpenAlex
Research works
59
▲ 152% vs 2013–17
Citations
202
3.4 per fractional work
Top-10% rate
12.1%
record average 16.5%
Open access
74%
world 28%

Not ranked overall: Protagonist Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.17× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 0.28× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 7.47× its world share, 2 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 4.62× its world share, 0 worksPharmacology, Toxico…Chemistry: 1.04× its world share, 0 worksChemistryComputer Science: 0.21× its world share, 0 worksComputer ScienceEngineering: 0.40× its world share, 1 worksEngineeringEnvironmental Science: 0.05× its world share, 0 worksEnvironmental ScienceHealth Professions: 0.50× its world share, 0 worksHealth ProfessionsMedicine: 2.17× its world share, 8 worksMedicineNursing: 0.42× its world share, 0 worksNursingArts and Humanities: 2.27× its world share, 1 worksArts and HumanitiesDecision Sciences: 0.42× its world share, 0 worksDecision SciencesPsychology: 0.32× its world share, 0 worksPsychologySocial Sciences: 2.20× its world share, 6 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 7.5×. Every wedge is a field page.

Which keywords describe research at Protagonist Therapeutics (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: JAK2 Mutation, Myelofibrosis, Pulmonary Hypertension, Public Policy, Sickle-cell Disease, Thalassemia, Epidemiology and Globalization.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 16 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 16 words, with their numbers
  1. Epidemiology3▲ 3.2×8 topics
  2. Globalization2▲ 5.2×5 topics
  3. JAK2 Mutation2▲ 428×1 topic
  4. Myelofibrosis2▲ 428×1 topic
  5. Public Policy2▲ 19×4 topics
  6. Pulmonary Hypertension2▲ 66×2 topics
  7. Sickle-cell Disease2▲ 200×1 topic
  8. Thalassemia2▲ 200×1 topic
  9. Social Movements2▲ 25×5 topics
  10. Colonialism1▲ 14×5 topics
  11. Inflammation1▲ 3.3×8 topics
  12. Territoriality1▲ 130×2 topics
  13. Sustainability1▲ 2.4×2 topics
  14. Pandemic1▲ 5.0×4 topics
  15. Segregation1▲ 69×1 topic
  16. Urbanization1▲ 14×1 topic

Which research topics does Protagonist Therapeutics (United States) publish most on?

By volume in 2022–2025: Myeloproliferative Neoplasms: Diagnosis and Treatment, Hemoglobinopathies and Related Disorders, Urban Development and Societal Issues and Iron Metabolism and Disorders.

Myeloproliferative Neopl…2Myeloproliferative Neoplasms: Diagnosis and Treatment: 2 fractional worksHemoglobinopathies and Related Disorders: 2 fractional worksUrban Development and Societal Issues: 1 fractional worksIron Metabolism and Disorders: 1 fractional worksUrban Design and Spatial Analysis: 0 fractional worksSMEs Development and Digital Marketing: 0 fractional worksAcute Myeloid Leukemia Research: 0 fractional worksCultural, Media, and Literary Studies: 0 fractional worksImmunodeficiency and Autoimmune Disorders: 0 fractional worksCytokine Signaling Pathways and Interactions: 0 fractional works
GeneticsUrban StudiesHematologyBuilding and Construction4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Myeloproliferative Neoplasms: Diagnosis and Treatment Genetics 2 works
  2. 2 Hemoglobinopathies and Related Disorders Genetics 2 works
  3. 3 Urban Development and Societal Issues Urban Studies 1 works
  4. 4 Iron Metabolism and Disorders Hematology 1 works
  5. 5 Urban Design and Spatial Analysis Building and Construction 0 works
  6. 6 SMEs Development and Digital Marketing Demography 0 works
  7. 7 Acute Myeloid Leukemia Research Hematology 0 works
  8. 8 Cultural, Media, and Literary Studies Philosophy 0 works
  9. 9 Immunodeficiency and Autoimmune Disorders Immunology 0 works
  10. 10 Cytokine Signaling Pathways and Interactions Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available73.9%not open26.1%

World: 28% of research is openly available.

with international co-authors47.7%domestic only52.3%

World: 19% is written across borders.

How has Protagonist Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 152% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Newark

All research institutions in Newark

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.